Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Sarcopenia in Advanced Serous Ovarian Cancer

(2017) Holger Bronger et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Ethical guidelines for publishing in the journal of cachexia, sarcopenia and muscle: update 2017

(2017) Stephan von Haehling et al.   Journal of Cachexia Sarcopenia and Muscle

Differential Bone Loss in Mouse Models of Colon Cancer Cachexia

(2017) Andrea Bonetto et al.   Frontiers in Physiology

Elevated Bone Turnover Markers after Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Breast and Ovarian Cancer

(2017) Ingrid E. Fakkert et al.   PLoS One

ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass

(2017) Rafael Barreto et al.   Scientific Reports

Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer

(2016) Amanika Kumar et al.   GYNECOLOGIC ONCOLOGY

Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs

(2016) Rafael Barreto et al.   Oncotarget

Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients

(2016) Iris J.G. Rutten et al.   Journal of Cachexia Sarcopenia and Muscle

Cancer and Chemotherapy Contribute to Muscle Loss by Activating Common Signaling Pathways

(2016) Rafael Barreto et al.   Frontiers in Physiology

Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes

(2016) T. A. Nissinen et al.   Scientific Reports

Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer

(2015) Ingrid E. Fakkert et al.   EUROPEAN JOURNAL OF CANCER

In vivo tumor growth of high-grade serous ovarian cancer cell lines

(2015) Anirban K. Mitra et al.   GYNECOLOGIC ONCOLOGY

Regulation of autophagy and the ubiquitin–proteasome system by the FoxO transcriptional network during muscle atrophy

(2015) Giulia Milan et al.   Nature Communications

Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations

(2015) Fabrizio Pin et al.   Oncotarget

Skeletal Muscle Depletion and Markers for Cancer Cachexia Are Strong Prognostic Factors in Epithelial Ovarian Cancer

(2015) Stefanie Aust et al.   PLoS One

Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations

(2014) F. Ricci et al.   CANCER RESEARCH

Sarcopenia as a Useful Predictor for Long-Term Mortality in Cirrhotic Patients with Ascites

(2014) Tae Yeob Kim et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Inflammation Based Regulation of Cancer Cachexia

(2014) Jill K. Onesti et al.   Biomed Research International

Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells

(2013) Zhiqiang Han et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer

(2013) Teng Ji et al.   CANCER LETTERS

Nutritional status, CT body composition measures and survival in ovarian cancer

(2013) Michelle L. Torres et al.   GYNECOLOGIC ONCOLOGY

A Study to Evaluate the Cause of Bone Demineralization in Gynecological Cancer Survivors

(2013) C. Stavraka et al.   ONCOLOGIST

Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research

(2013) Michael S. Anglesio et al.   PLoS One

Evaluating cell lines as tumour models by comparison of genomic profiles

(2013) Silvia Domcke et al.   Nature Communications

JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia

(2012) Andrea Bonetto et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: Altered energetic efficiency?

(2012) Cibely Cristine Fontes-Oliveira et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: Relationships with depression, fatigue, and disability

(2012) Andrew Schrepf et al.   BRAIN BEHAVIOR AND IMMUNITY

Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways

(2012) Kenneth C.H. Fearon et al.   Cell Metabolism

Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results

(2012) Lene Thoresen et al.   CLINICAL NUTRITION

Inflammation and ovarian cancer

(2012) Antonio Macciò et al.   CYTOKINE

Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2

(2012) Sharon Cohen et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

NIH Image to ImageJ: 25 years of image analysis

(2012) Caroline A Schneider et al.   NATURE METHODS

Paraneoplastic Thrombocytosis in Ovarian Cancer

(2012) Rebecca L. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ten-Year Relative Survival for Epithelial Ovarian Cancer

(2012) Lauren A. Baldwin et al.   OBSTETRICS AND GYNECOLOGY

IL-6 regulation on skeletal muscle mitochondrial remodeling during cancer cachexia in the ApcMin/+ mouse

(2012) James P White et al.   Skeletal Muscle

Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients

(2011) Denis Lane et al.   BMC CANCER

Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity

(2011) Carla MM Prado et al.   CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE

STAT3 Activation in Skeletal Muscle Links Muscle Wasting and the Acute Phase Response in Cancer Cachexia

(2011) Andrea Bonetto et al.   PLoS One

Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma

(2010) S. Antoun et al.   ANNALS OF ONCOLOGY

Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells

(2010) Yue Wang et al.   CANCER LETTERS

Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival

(2010) Xiaolan Zhou et al.   CELL

Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”

(2010) M. Muscaritoli et al.   CLINICAL NUTRITION

Guidelines for assessment of bone microstructure in rodents using micro-computed tomography

(2010) Mary L Bouxsein et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cisplatin triggers atrophy of skeletal C2C12 myotubes via impairment of Akt signalling pathway and subsequent increment activity of proteasome and autophagy systems

(2010) Alessandro Fanzani et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia

(2009) Margaret E. Benny Klimek et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Epithelial-to-Mesenchymal Transition and Ovarian Tumor Progression Induced by Tissue Transglutaminase

(2009) M. Shao et al.   CANCER RESEARCH

Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

(2007) William E. Winter et al.   JOURNAL OF CLINICAL ONCOLOGY